PUBLISHER: The Business Research Company | PRODUCT CODE: 1703099
PUBLISHER: The Business Research Company | PRODUCT CODE: 1703099
Cell therapy human raw materials encompass biological substances derived from human sources, including cells, tissues, and blood components, utilized as foundational elements in the development and manufacturing of cell-based therapeutic products. These raw materials play crucial roles in various stages of cell therapy production aimed at creating treatments for diseases such as cancer, genetic disorders, and degenerative conditions.
The primary product types of cell therapy human raw materials include cell culture media, cell culture serum, cell culture supplements, reagents and buffers, and others. Cell culture media are solutions designed to provide nutrients and an optimal environment for cell growth outside their natural setting, which is essential for laboratory-based cell studies. These products find application in various types of cell therapies, including dendritic cell therapy, natural killer (NK) cell therapy, stem cell therapy, and T-cell therapy. End users encompass biopharmaceutical and pharmaceutical companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), as well as academic and research institutions.
The cell therapy human raw materials market research report is one of a series of new reports from The Business Research Company that provides cell therapy human raw materials market statistics, including cell therapy human raw materials industry global market size, regional shares, competitors with an cell therapy human raw materials market share, detailed cell therapy human raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy human raw materials industry. This cell therapy human raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cell therapy human raw materials market size has grown exponentially in recent years. It will grow from $2.82 billion in 2024 to $3.39 billion in 2025 at a compound annual growth rate (CAGR) of 20.4%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, high demand for regenerative medicines, governmental funding and support, and growing healthcare expenditure.
The cell therapy human raw materials market size is expected to see exponential growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 20.1%. The growth in the forecast period can be attributed to expanding therapeutic applications, rising patient awareness, favorable regulatory frameworks, a growing biopharmaceutical sector, and improved manufacturing processes. Major trends in the forecast period include the adoption of allogeneic therapies, the integration of artificial intelligence, an increase in off-the-shelf cell therapies, the use of 3D bioprinting technology, and the and the development of hybrid cell therapies.
The growing adoption of regenerative medicine is expected to propel the cell therapy human raw materials market in the coming years. Regenerative medicine aims to repair, replace, or regenerate damaged tissues and organs by utilizing the body's inherent regenerative abilities or external methods such as stem cells, tissue engineering, or gene therapy, all with the goal of restoring normal function. The increased prominence of regenerative medicine is driven by advancements in biotechnology, a better understanding of cellular mechanisms, the rising demand for personalized medicine, and its potential to address previously unmet medical needs. Cell therapy and human raw materials play a crucial role in this progress by supplying the necessary biological components for cell-based therapies, which are essential for creating standardized and reliable treatments for various health conditions. For example, a report from the Alliance for Regenerative Medicine, a US-based non-profit, revealed that in Q1 2023, there were 2,760 cell, gene, and tissue-engineering therapeutic developers globally, marking a 101% increase from 1,369 in Q1 2022. As a result, the increasing adoption of regenerative medicine is fueling the growth of the cell therapy human raw materials market.
Leading companies in the cell therapy human raw materials market are increasingly focusing on the development of chemically defined cell culture media to expedite cell therapy development. A cell culture medium is a nutrient-rich solution designed to furnish essential nutrients, growth factors, and environmental conditions necessary for the in vitro growth and propagation of cells outside their natural environment. For example, in May 2023, Lonza Group AG, a Switzerland-based healthcare manufacturing organization, introduced the TheraPEAK T-VIVO Cell Culture Medium, featuring a chemically defined formulation, serum-free and animal component-free composition, recombinant proteins, enhanced culture and expansion support, and application assistance, ensuring consistency, safety, and regulatory compliance in cell therapy manufacturing. This medium represents significant technological advancements by eliminating animal components, adopting a chemically defined formulation, and incorporating regulatory-friendly characteristics, thereby contributing to improved safety, quality, and regulatory compliance.
In January 2022, Thermo Fisher Scientific Inc., a US-based scientific research and laboratory services company, completed the acquisition of PeproTech Inc. for $1.85 billion. This strategic acquisition expands Thermo Fisher's recombinant protein portfolio, aligns with its biosciences business, and strengthens its market position, impacting the cell therapy human raw materials market by enhancing product offerings and market capabilities. PeproTech Inc. is a US-based biotechnology company specializing in manufacturing products for life science research, including cytokines, antibodies, and cell culture media.
Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.
North America was the largest region in the cell therapy human raw materials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cell therapy human raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cell therapy human raw materials market consists of sales of primary cells, stem cell banks, tissue scaffolds, cryopreservation media, cell separation products, and extracellular matrices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cell Therapy Human Raw Materials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cell therapy human raw materials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cell therapy human raw materials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell therapy human raw materials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.